METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests whether the drug miricorilant can safely reduce liver fat in adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. About 175 participants will receive either the drug or a placebo, and doctors will measure liver fat changes using MRI. Th…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New drug targets fatty liver in people with a common gene variant
Disease control OngoingThis early-phase study tests a new medicine called LY3849891 in adults with a type of fatty liver disease (MASLD) who carry a specific gene variant (PNPLA3 I148M). The main goal is to check the drug's safety and how the body processes it. Researchers will also use blood tests and…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 22, 2026 14:03 UTC